ProjectsItalian Version
| Date | Title | Synopsis and Results | Proposer |
|---|---|---|---|
| 2023-12-31 | Evaluating the efficacy of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter retrospectIve sTudY (OPPORTUNITY). | ... read more |
Francesco Patti |
| 2023-12-31 | Secondary prevention in multiple sclerosis: “Bacille Calmette-Guérin" (BCG) vaccine in people with radiologically isolated syndrome (RIS). | ... read more |
Giovanni Ristori |
| 2023-12-31 | SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: a propensity score matched case-control study | The association between intercurrent viral respiratory infections and exacerbations of
Multiple Sclerosis (MS) disease activity has been for many years an open question.
This is a propensity score matched, case-control, observational study in a single-center
cohort of patients with relapsing-remitting MS (RRMS) who tested positive for SARS-CoV-2
in ... read more |
Paola Cavalla |
| 2022-12-31 | OCREVID Study (The management of OCRElizumab during the coVID-19 pandemic in Italy) | ... read more |
Antonio Gallo |
| 2022-12-31 | Multiple Sclerosis disease activity and SARS-COV2 pandemic: a population based study from the Italian MS Registry | ... read more |
Marco Capobianco |
| 2022-12-01 | Validate a case definition of multiple sclerosis (MS) using different electronic (health and social) record: case study on selected provinces of Emilia Romagna Region. | ... read more |
Mario Alberto Battaglia |
| 2022-09-30 | PROfiling the risk of Severe Adverse Events during sequencing therapies in patients with multiple sclerosis: an observational cohort analysis based on Italian Multiple Sclerosis Registry. | ... read more |
Damiano Paolicelli |
| 2022-06-15 | Early prediction of unfavorable evolution of Clinically Isolated Syndrome (CIS) patients | In the last years there is a growing interest about patients with clinically isolated syndrome (CIS) suggestive for multi-focal inflammatory demyelinating disease of the central nervous system. These cases can evolve to clinically definite multiple sclerosis (CDMS), before which a disease-free status can last for an unpredictable time. Recently, th ... read more |
Roberto Bergamaschi |
| 2022-05-26 | Clinical characteristics and disease outcomes of late onset Multiple Sclerosis: a retrospective multicenter study. | ... read more |
Lorena Lorefice |
| 2022-05-26 | Comparative effectiveness of different Natalizumab dosing schedules in real world life: a retrospective Italian multicentre study | ... read more |
Francesco Patti |
| 2022-05-26 | Comparative effectiveness of initial Treatment Choices for Multiple Sclerosis: a multicentre study | ... read more |
Emanuele D'Amico |
| 2022-05-26 | Exploring phenotype and recovery from relapses in relapsing-remitting multiple sclerosis patients: old versus new Disease-Modifying Therapies | ... read more |
Emanuele D'Amico |
| 2022-05-26 | Demographic, clinical and treatment factors associated with the risk and severity of Covid-19 in people with Multiple Sclerosis | ... read more |
Maria Trojano |
| 2022-05-26 | HETEROGENEITY Study. Are multiple sclerosis (MS) phenotypes influenced by the type of referral MS center? | ... read more |
Roberto Bergamaschi |
| 2022-04-26 | Silent progression in an Italian CIS and Relapsing-Remitting MS cohort | Objectives. To analyze, in a big Italian multicentric cohort of CIS and RRMS patients, data regarding the silent disease progression independent from relapse activity and MRI data, comparing treated - with "platform" and "highly active" therapies - and untreated patients.
Methods. Patients with: age >18 years; a CIS or RRMS diagnosis made using the ... read more |
Maria Pia Amato - Bellinvia |
| 2021-12-31 | Big Multiple Sclerosis Data (BMSD) network | ... read more |
Maria Trojano |
| 2021-12-31 | The concept of persistence in disability improvement: an application of Markov model to treated patients from the Italian Registry | ... read more |
Matilde Inglese |
| 2021-12-31 | Autologous Hematopoietic Stem Cell Transplantation For Secondary Progressive Multiple Sclerosis: a comparative study with matched control patients from the Italian Multiple Sclerosis Register | ... read more |
Matilde Inglese |
| 2021-12-31 | Assessing early clinical and MRI predictors of treatment response in pediatric multiple sclerosis patients. | ... read more |
Maria Pia Amato/De Meo |
| 2021-10-28 | EPID-MS Evaluation of the drivers of the therapy switch in active RRMS and active SPMS patients. | ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2020-11-01 | Assessing Efficacy and Safety of treatments in progressive Multiple Sclerosis | Except for Ocrelizumab, previous phase-III randomized controlled trials largely failed in finding benefit of disease modifying drugs (DMDs) among patients affected by primary progressive multiple sclerosis (PPMS). Consistently with these findings, most of the Real word studies drove to the same conclusion, finding no substantial differences between ... read more |
Maria Pia Amato |
| 2020-10-15 | E-MUSIC: Early MUltiple Sclerosis Italian Cohort | Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is characterized by inflammation, demyelination, and degenerative changes. Most individuals are diagnosed with MS at age 20–40 years. Pediatric-onset MS (POMS), before the age of 18, represents 3-10% of the whole MS population, while late-onset ... read more |
Maria Pia Amato-Mattia Fonderico |
| 2020-09-15 | Predictive factors of disability progression in a large cohort of italian multiple sclerosis patients | Multiple sclerosis (MS) is one of the most common cause of neurological disability in young adults globally. It is a chronic degenerative illness and therefore carries a high economic and quality of life burden associated with it. One of the principal objectives in the care of people with MS is, therefore, to reduce the irreversible accumulation of ... read more |
Marzia Romeo |
| 2020-07-15 | INTEREST. Italian Multiple Sclerosis Registry non interventional retrospective analysis in secondary progressive multiple sclerosis | The distinction between relapsing-remitting (RR) MS and progressive phenotypes remains a critical challenge for the neurologist in real clinical practice: currently there are not specific parameters or validated biomarkers to address the diagnostic doubt, which remains entrusted to clinical experience. In fact, in clinical practice secondary progre ... read more |
Maria Trojano |
| 2020-06-15 | Retrospective pilot study on long-term Cladribine effects in patients with relapsing remitting multiple sclerosis or clinically isolated syndrome. | The aim of this Italian pilot study call CLARINET-MS study is to explore the feasibility of the retrospective approach for evaluating effectiveness in subjects previously treated with Cladribine and then followed as per clinical practice.
The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with mu ... read more |
Francesco Patti |
| 2020-06-15 | Early-aggressive treatment algorithm versus classical escalation therapy in relapsing Multiple Sclerosis | The most important goal of multiple sclerosis (MS) therapy is the prevention of long-term disability accumulation. The therapeutic scenario for relapsing–remitting MS (RRMS) has widely expanded during the past 20 years. Choosing the MS therapy has become increasingly complex, due to the difficulties in weighing the risk/benefit ratio of several dif ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2020-06-15 | Risks associated with Wash-Out Duration when switching from Fingolimod to cell-depleting agents | Decisions regarding the duration of washout periods between disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients need to take both the risk of disease reactivation and safety issues regarding overlapping immunological mechanisms of action into account.
Fingolimod is an oral DMT, approved for the treatment of highly active relapsin ... read more |
Diana Ferraro |
| 2020-06-15 | Assessing the clinical course of pediatric onset multiple sclerosis in different treatment eras: are we really modifying the disease? | Availability of new disease modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear if this improvement also involves pediatric-onset MS (POMS) patients, whose early management is limited by a low number of approved DMTs and, possibly, othe ... read more |
Damiano Baroncini |
| 2020-04-24 | The use of a roving EDSS reference value to enhance detection of EDSS worsening events: A real world evaluation through the Italian MS Register. | Disease registries are recognized as providing meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments for patients with chronic diseases. Data collected in a register are also useful for observational research on sample populations treated and followed in real-world conditions. The result provide ... read more |
Paola Mosconi |
| 2019-12-15 | Retrospective study to evaluate the long-term impact of different treatment strategies on disability outcomes in patients with Relapsing Multiple Sclerosis. Italian IMedWeb MS Registry. RE.LO.DI.MS Study | The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies.
To evaluate different therapeutic s ... read more |
Damiano Paolicelli |
| 2019-06-15 | INSPIRA - Italian analysis of the National multiple sclerosis registry Studying the concept of Progression Independent from Relapse Activity | To date, secondary-progressive multiple sclerosis (SPMS) is diagnosed retrospectively by neurologists, according to the Lublin’ definition: a history of a gradual disability progression, independent of relapses, after an initial relapsing course. No biological nor clinical markers are available to make more sensitive and reliable the identification ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2017-10-14 | Profiling treatment choices in MS during two different eras: a real world assessment in the Italian MS Registry | ... read more |
Maria Trojano-Pietro Iaffaldano |